You are here: Industry Insights > lung cancer

News List

Pfizer’s lorlatinib impresses in Phase II lung cancer trial pharmatimes
October 18, 2017
Pfizer has presented Phase II data showing that its next-generation tyrosine kinase inhibitor lorlatinib exhibited “clinically meaningful activity” against lung tumours and brain metastases.
Anti-inflammatory therapy cuts risk of lung cancer worldpharmanews
August 29, 2017
In most clinical trials for cancer therapy, investigators test treatments in patients with advanced disease.
Biocept, UT Southwestern Medical Center Announce Clinical Study Agreement americanpharmaceuticalreview
August 18, 2017
Biocept has entered into a clinical study agreement with the University of Texas Southwestern Medical Center.the study is designed to evaluate the clinical utility of Biocept's Target Selector platform for patients diagnosed with ALK-positive non-small ce
Opdivo (Nivolumab) Receives 1st August PBS Listings For Advanced Lung Cancer And Advanced Kidney Can firstwordpharma
August 02, 2017
OPDIVO® becomes the first and only immuno-oncology therapy PBS listed for advanced lung and kidney cancer1,2
AZ immunotherapy gets FDA boost in early lung cancer pharmaphorum
August 01, 2017
The FDA may have offered struggling AstraZeneca a lifeline, granting a “breakthrough” designation for its cancer immunotherapy Imfinzi in early-stage lung cancer.
Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer academic.oup.com
July 24, 2017
After adjusting for inflation, the price per life-year gained of cancer drugs rose from $54 100 to $207 000 over the 20-year time period between 1995 and 2013 (1).
Novartis gains first-line approval for Zykadia in lung cancer pharmafile
June 30, 2017
Novartis gains first-line approval for Zykadia in lung cancer
Scientists discover new type of immune cell to guide immunotherapy for lung cancer pharmaceutical-technology
June 28, 2017
A new Cancer Research UK funded study has revealed that the discovery of a new type of immune T-cell could guide immunotherapy for lung cancer patients.
Novartis lung cancer combo receives FDA approval pharmafile
June 23, 2017
Novartis has revealed that its drug Tafinlar (dabrafenib) has received approval from the FDA for use in combination with Mekinist (trametinib) in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours express the BRAF V
FDA approves Roche’s lung cancer companion diagnostic europeanpharmaceuticalreview
June 07, 2017
The US Food and Drug Administration (FDA) have approved Roche’s VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page